Systemic drug-related intertriginous and flexural exanthema-like eruption after Oxford-AstraZeneca COVID-19 vaccine

Table 1 Reported cases of SDRIFE-like eruption secondary following COVID-19 vaccination

Reported case	Vaccine type	Age / sex of patient	Onset after injection	N° of vaccine doses prior to SDRIFE	Treatment
Orenay et al. (2021)¹²	CoronaVac	87 M	4 days	N/A	Oral prednisolone 40 mg/day (3 weeks including tapering off); topical corticosteroids; oral antihistamines
Lim & Wylie (2021)¹³	Vaxzevria (ChAdOx1 nCoV-19)	61 M	1 day	2	Oral prednisolone 30 mg/day (4 weeks including tapering off); topical corticosteroids and antifungals
Hai et al. (2021)¹⁴	Comirnaty (BNT162b2)	23 M	6 weeks	2	Topical corticosteroid
Hai et al. (2021)¹⁴	Comirnaty (BNT162b2)	38 F	2 weeks	2	Oral prednisolone 40 mg/day (9 days including tapering off); topical corticosteroid
Bellinato et al. (2021)⁴	Comirnaty (BNT162b2)	65 M	2 weeks	N/A	N/A
Hong et al. (2022)¹⁵	Vaxzevria (ChAdOx1 nCoV-19)	53 M	7 days	2	Oral prednisolone 30 mg/day (2 weeks including tapering off)
Lahouel et al. (2022)¹⁶	Comirnaty (BNT162b2)	52 F	5 days	2	None (spontaneous remission after 5 days)
Lahouel et al. (2022)¹⁶	CoronaVac	57 F	3 days	2	Topical corticosteroids; oral antihistamine
Manaa et al. (2022)¹⁷	Comirnaty (BNT162b2)	59 M	2 days	3	Oral prednisone 40 mg/day (1 month including tapering off); cyclosporine 2.5 mg/kg/day (2.5 months including tapering off); topical corticosteroids
Our case	Vaxzevria (ChAdOx1 nCoV-19)	67 F	5 days	2	Topical corticosteroids (20 days)

ISSN: 1476-7961